États-Unis · Presse financière · Investor's Business Daily

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened

Publié par Investor's Business Daily · États-Unis il y a 2 h

Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, Filspari. The post Travere Is On A Crash Course With…

Lire l'article complet sur Investor's Business Daily Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.investors.com)

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened

À lire aussi

Stocks Are Mixed After Apple Earnings Disappoint

Midterms, Markets, and Earnings Malaise. Apple and Palantir Sum Up the Mood.

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened

Partager

À lire aussi

Stocks Are Mixed After Apple Earnings Disappoint

Midterms, Markets, and Earnings Malaise. Apple and Palantir Sum Up the Mood.